End of the New Zealand asthma mortality epidemic

In 1989, a case-control study reported that inhaled fenoterol was associated with the epidemic of asthma deaths that had affected New Zealand since 1976. The New Zealand Department of Health issued warnings about the safety of fenoterol and restricted its availability. The associated time trends are consistent with the hypothesis that fenoterol was the main factor in the New Zealand asthma mortality epidemic. The epidemic commenced when fenoterol was introduced in 1976, and the New Zealand death rate remained the highest in the world for more than a decade. After publication of the case-control study, the death rate fell by half and has now remained low for a further 3 years (1990-92). Time-trend data do not suggest a class effect of inhaled beta-agonists in the epidemic: there was no association between beta-agonist sales and the start of the epidemic, and total sales of inhaled beta-agonists actually increased slightly during 1989-90 when the epidemic came to an end. Time-trend data are also inconsistent with the hypothesis that the epidemic may have occurred because of underprescribing of inhaled corticosteroids. Similarly, time-trend data is incosistent with hypotheses postulating a major role of social factors such as unemployment. Data on time trends should be assessed with caution, because time trends in asthma deaths can be affected by many factors. Nevertheless, the New Zealand time trends are consistent with fenoterol being the main cause of the New Zealand asthma mortality epidemic and are inconsistent with a significant role for other suggested causes.

[1]  L. Doolan,et al.  Iatrogenic drug‐induced acute renal failure , 1992, The Medical journal of Australia.

[2]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[3]  N. Pearce,et al.  Asthma deaths in New Zealand. , 1992, BMJ.

[4]  W. Spitzer,et al.  Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management. , 1991, Chest.

[5]  N. Pearce,et al.  β-Agonist Use and Death from Asthma , 1994 .

[6]  N. Pearce,et al.  Albuterol and deaths from asthma in New Zealand from 1969 to 1976: A case‐control study , 1992, Clinical pharmacology and therapeutics.

[7]  H. Staudinger,et al.  Asthma deaths in New Zealand. , 1992, BMJ.

[8]  N. Pearce,et al.  PRESCRIBED FENOTEROL AND DEATH FROM ASTHMA IN NEW ZEALAND, 1981-83; CASE-CONTROL STUDY , 1989, The Lancet.

[9]  E. Mitchell,et al.  Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81. , 1984, British medical journal.

[10]  N. Pearce,et al.  Asthma mortality and inhaled beta agonist therapy. , 1991, Australian and New Zealand journal of medicine.

[11]  J. Wilson,et al.  HAS THE CHANGE TO BETA-AGONISTS COMBINED WITH ORAL THEOPHYLLINE INCREASED CASES OF FATAL ASTHMA? , 1981, The Lancet.

[12]  B. Mullen,et al.  The Association Between β-Agonist Use and Death From Asthma: A Meta-analytic Integration of Case-Control Studies , 1993 .

[13]  M. Sears,et al.  Accuracy of certification of deaths due to asthma. A national study. , 1986, American journal of epidemiology.

[14]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[15]  A. Buist,et al.  A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. , 1994, American journal of respiratory and critical care medicine.

[16]  R. Beaglehole,et al.  Mortality from asthma: a new epidemic in New Zealand , 1982, British medical journal.

[17]  N. Pearce,et al.  Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. , 1990, Thorax.

[18]  Asthma deaths in New Zealand. , 1992, BMJ.

[19]  E. Mitchell,et al.  Trends in hospital admission rates and drug treatment of asthma in New Zealand. , 1983, The New Zealand medical journal.

[20]  J Crane,et al.  Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. , 1991, Thorax.

[21]  N. Pearce,et al.  Beta agonists and asthma mortality: déjà vu , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  P. Davis,et al.  The impact of the new subsidy regime in general practice in New Zealand. , 1994, Health policy.

[23]  N. Pearce,et al.  Beta-agonists and death from asthma. , 1992, The New England journal of medicine.